Novartis AG (NYSE:NVS) posted new clinical study updates in NSCLC at the recently held ASCO 2019 Annual Meeting. This comprised primary efficacy data from the GEOMETRY mono-1 Phase 2 clinical study. It showed that INC280 comes as a potential treatment alternative for subjects with metastatic or locally advanced NSCLC that has MET exon-14 skipping mutation. As of now, there are no permitted targeted therapies to cure this aggressive form of NSCLC. Data of the Phase II trial were planned to be showcased at an oral session at ASCO, June 3, 2019.
John Tsai, MD, the Chief Medical Officer at Novartis, expressed that new lung cancer treatment alternatives are critical, as this disease affects over 2 million new people around the world annually. The data from GEOMETRY mono-1 trial is promising, and they look forward to bringing this data ahead of health authorities.
Worldwide, lung cancer leads to more deaths than breast, prostate, and colon cancer combined, and over two million new instances of lung cancer are known each year. Despite treatment developments, people with NSCLC still show a poor diagnosis and limited treatment alternatives. This includes almost 70% of NSCLC people who suffer genomic mutation.
Novartis’s research has assisted in transform treatment options for patients struggling with NSCLC. The company continues its commitment to the international lung cancer community through underway trials, and as the study of investigational compounds in NSCLC.
In other news, Swiss drugmaker Novartis reported that it won U.S. nod for its gene treatment Zolgensma for spinal muscular atrophy, the major genetic cause of death in kids, and priced the one-time therapy at $2.125 million. The company defended the huge price stating that a one-time treatment mark as more valuable as compared to other expensive long-term therapies.
The FDA approved Zolgensma for infants under the age of two with spinal muscular atrophy, including those not yet displaying symptoms. The nod covers children with the lethal form of the inborn disease and those with forms where debilitating indications may set in later.